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An ideal, single stage vaccine useful for elimination of
Plasmodium falciparum (Pf) would prevent infection at
the pre-erythrocytic stage of the parasite life cycle, thereby
preventing all Pf-caused disease and transmission from
humans to mosquitoes. The only approach to immuniza-
tion shown to consistently induce greater than 90% pro-
tection against infection and protection sustained for at
least 10-28 months has been immunization by mosquito
bite with whole Pf sporozoites (SPZ) of two types. The
first type, radiation-attenuated PfSPZ, invade hepatoctyes
and expresses new proteins, but cannot replicate. The
second type fully develop in hepatocytes, producing tens
of thousands of merozoites that invade erythrocytes, but
are unable to fully develop within erythrocytes because
they are killed by an antimalarial drug. This approach
called chemoprophylaxis with sporozoites (CPS) harnesses
the infectious agent’s inherent replicative properties to
amplify production of protective immunogens spanning
multiple developmental stages, and then eliminates the
infectious agent with an anti-infective drug before the
onset of disease. Sanaria was founded to develop PfSPZ
vaccines. The first vaccine developed and tested was the
PfSPZ Vaccine. The PfSPZ Vaccine is comprised of asep-
tic, purified, radiation attenuated, cryopreserved PfSPZ. It
was shown to be safe and well-tolerated when adminis-
tered ID or SC to 80 volunteers in the U.S., but sub-
optimally immunogenic. It is now being tested in the U.S.
and soon in Tanzania when administered by IV injection,
since it induced high levels of PfSPZ-specific CD8+ T cells
in the livers of immunized non-human primates when
administered IV. A second product, PfSPZ Challenge, is
comprised of non-irradiated, fully infectious PfSPZ. PfSPZ
Challenge has been shown to infect 100% of volunteers
after ID or IM administration by needle and syringe. It has
been or will be tested for optimization of adminstration by
the ID, IM, and IV routes in 2012 or early 2013 in the
Netherlands, UK, Tanzania, U.S., Germany, Spain, and
Kenya. A third product, PfSPZ-CVac, is comprised of
PfSPZ Challenge administered to volunteers receiving
chloroquine chemoprophylaxis. It will be assessed in 2012-
2013 in the Netherlands, Mali, Germany and Tanzania.
Assessment of these three products in synergistic, interac-
tive and adaptive clinical trials will facilitate progress
toward optimizing administration and dosage regimen of
all three whole PfSPZ products, as well as those developed
in the future from genetically altered parasites, thereby
facilitating licensure of one or more PfSPZ-based vaccines.
Progress and plans for development will be discussed.
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